Browse News

Found 5,450 articles

• CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer

  10/22/2019

  Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer

• Nearly 60 Percent Of Blood Cancer Patients Covered By Medicare Delay Or Forgo Treatment; One Factor Could Be The High Cost Of Cancer Care

  10/21/2019

  A new study commissioned by The Leukemia & Lymphoma Society finds that patients can still face steep out-of-pocket costs three years after initial diagnosis; consumers should closely consider their coverage options during open enrollment

• The Multiple Myeloma Research Foundation (MMRF) Honors General Colin L. Powell At Chicago Awards Dinner

  10/18/2019

  The Multiple Myeloma Research Foundation (MMRF) was honored to have General Colin L. Powell (Ret.) as the keynote speaker at the annual MMRF Chicago Awards Dinner fundraiser at the Four Seasons Chicago on October 17, 2019.

• Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

  10/18/2019

  Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L (CPS ≥1)

• Study finds racial disparities in treatment of multiple myeloma patients

  10/17/2019

  Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances

• Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

  10/17/2019

  Selexis SA and Teneobio, Inc. announced that they have signed three commercial license agreements for the development of Teneobio’s Human Heavy-Chain Antibodies, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer.

• Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

  10/16/2019

  Sutro discovered and manufactures STRO-002 using its proprietary XpressCF+™ cell-free protein synthesis technology.

• Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma

  10/16/2019

  Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of a first-in-human, Phase 1 clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or multiple myeloma (MM).

• Myeloma Canada Launches Award-Winning Myeloma Monitor for Shared Decision-Making

  10/16/2019

  Application Empowers Patients in Managing and Taking Control of their Disease

• Johnson & Johnson Reports 2019 Third-Quarter Results

  10/15/2019

  Johnson & Johnson announced results for third-quarter 2019.

• Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team

  10/15/2019

  Amgen (NASDAQ:AMGN) today announced the expansion of Myeloma MVP™, a national initiative to help myeloma patients and their care teams create their Most Valuable Plan.

• Ichnos Sciences Launches as New, Independent, Leading-Edge Biotech Dedicated to Outpacing Disease

  10/15/2019

  Ichnos ('īk-nōz) Sciences officially opened its doors to the world today as an independent, fully integrated, global biotech company

• Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

  10/15/2019

  Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an additional $40.2 million in the company's Series B financing, for a total of $75.2 million in this financing

• Kleo Pharmaceuticals to Present at 2019 BIO Investor Forum

  10/15/2019

  Kleo Pharmaceuticals Inc. announced that its CEO Doug Manion, M.D., FRCP, will present at the 2019 BIO Investor Forum, which will be held at the Westin St. Francis Union Square in San Francisco on October 22-23rd.

• I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China

  10/14/2019

  I-Mab Biopharma and MorphoSys AG announced that I-Mab has received Investigational New Drug clearances from the National Medical Products Administration of China to expand the ongoing phase II and III clinical trials of TJ202/MOR202, MorphoSys's human monoclonal anti-CD38 antibody for the treatment of multiple myeloma, also to mainland China.

• Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.

  10/11/2019

  Kangpu Biopharmaceuticals announced that it has successfully completed a first-in-human phase I single ascending dose clinical study of KPG-818 conducted in the United States.

• Multiple Myeloma Research Foundation (MMRF) Launches Groundbreaking Direct-to-Patient Registry

  10/10/2019

  The Multiple Myeloma Research Foundation (MMRF) announced today the launch of its Direct-to-Patient (DTP) Registry, a cornerstone of its CureCloud® Initiative. By going directly to patients with an online consent, any patient diagnosed in the contiguous US can participate

• Nomination Committee Appointed in Respect of AGM 2020 in Oncopeptides

  10/10/2019

   According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on May 21st, 2019, the Nomination Committee for the annual general meeting 2020 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30th,

• Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2019

  10/10/2019

  Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group's financial figures.

• bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

  10/9/2019

  bluebird bio, Inc. (Nasdaq: BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia.